Ajanta Pharma Limited (AJANTPHARM)
ISIN: INE031B01049 Industry: Drug Manufacturers—Specialty & Generic Sector: Healthcare Website
1228.5
-5.8(-0.47%)

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets finished dosages. The company markets and serves various therapeutic segments, such as anti-biotic, anti-malarial, anti-diabetic, cardiology, gynecology, pediatric, respiratory and general health products, dermatology, ophthalmology, and pain management areas. It also provides multivitamins, antibiotics, eye drops, cough syrups, etc. The company serves in India, Africa, rest of Asia, the United States, and internationally. It supplies its products to government bodies, including armed forces, government hospitals, canteens, stores department, etc. The company was founded in 1973 and is headquartered in Mumbai, India.

Pricing Updates

TODAY'S HIGH

1247.3

TODAY'S LOW

1221.05

52 WEEK HIGH

1569.3334

52 WEEK LOW

1061.7667

Major Holders

% of Shares Held by
All Insider

70.73%

% of Shares Held by
Institutions

17.01%

% of Float Held by
Institutions

58.10%

Number of Institutions
Holding Shares

58

Company Overview

MARKET CAP

15740.15 Cr.

ETERPRISE VALUE

15231.44 Cr.

NO. OF SHARES

12.81 Cr.

BOOK VALUE

281.191

DIV. YIELD

7%

DEBT

28.48 Cr.

GROSS PROFIT

2457.01 Cr.

CASH

614.65 Cr.

REVENUE

3597.23 Cr.

REVENUE/SHARE

279.244

OHLC Chart 1y 2y 5y 10y

Price Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Volumes Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Cashflows

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Investments28.78 Cr.-96.26 Cr.-1.68 Cr.117.81 Cr.
Change To Liabilities-48.02 Cr.11.15 Cr.132.81 Cr.-24.29 Cr.
Total cashflows from Investing Activities-74.10 Cr.-282.39 Cr.-224.41 Cr.-222.78 Cr.
Net Borrowings-16.37 Cr.-59.29 Cr.-5.54 Cr.34.18 Cr.
Total Cash from Financing Activities-460.04 Cr.-318.29 Cr.-128.63 Cr.-147.46 Cr.
Other Liabilities142.97 Cr.20.42 Cr.71.34 Cr.40.59 Cr.
Total Assets0000
Net Income712.68 Cr.653.87 Cr.467.70 Cr.386.97 Cr.
Change in Cash27.90 Cr.-24.37 Cr.103.74 Cr.4.27 Cr.
Effect of Exchange Rate0000
Total Cash from Operating Activities562.04 Cr.576.31 Cr.456.77 Cr.374.51 Cr.
Depreciation125.30 Cr.111.40 Cr.92.48 Cr.69.05 Cr.
Other Cashflows from Investing Activities27.58 Cr.-16.23 Cr.11.20 Cr.1.75 Cr.
Dividends Paid-82.21 Cr.-82.90 Cr.-113.44 Cr.-79.12 Cr.
Change to Inventory-25.66 Cr.-271.45 Cr.-58.93 Cr.-85.33 Cr.
Change to Account Receivables-269.68 Cr.31.13 Cr.-268.38 Cr.-14.43 Cr.
Other Cashflows from Financing Activities-75.87 Cr.-40.69 Cr.-9.65 Cr.-2.52 Cr.
Change to Net Income-75.55 Cr.15.10 Cr.16.51 Cr.-1.08 Cr.
Capital Expenditures-148.84 Cr.-171.61 Cr.-239.42 Cr.-342.97 Cr.

Financials

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Research DevelopmentNoneNoneNoneNone
Effect of Accounting ChargesNoneNoneNoneNone
Income Before Tax909.48 Cr.900.18 Cr.663.97 Cr.514.27 Cr.
Minority InterestNoneNoneNoneNone
Net Income804 Cr.892.24 Cr.595.97 Cr.494.58 Cr.
Selling General Administrative645.78 Cr.552.30 Cr.489.01 Cr.450.32 Cr.
Gross Profit2508.72 Cr.2206.45 Cr.1898.23 Cr.1643.25 Cr.
Ebit804 Cr.892.24 Cr.595.97 Cr.494.58 Cr.
Operating Income804 Cr.892.24 Cr.595.97 Cr.494.58 Cr.
Other Operating Expenses933.64 Cr.645.82 Cr.717.53 Cr.626.97 Cr.
Interest Expense-10.20 Cr.-8.27 Cr.-11.91 Cr.-1.16 Cr.
Extraordinary ItemsNoneNoneNoneNone
Non RecurringNoneNoneNoneNone
Other ItemsNoneNoneNoneNone
Income Tax Expense196.80 Cr.246.31 Cr.196.27 Cr.127.30 Cr.
Total Revenue3340.99 Cr.2889.69 Cr.2587.87 Cr.2055.37 Cr.
Total Operating Expenses2536.99 Cr.1997.45 Cr.1991.90 Cr.1560.79 Cr.
Cost of Revenue832.27 Cr.683.24 Cr.689.64 Cr.412.12 Cr.
Total Other Income Expense Net105.48 Cr.7.94 Cr.68 Cr.19.69 Cr.
Discontinued OperationsNoneNoneNoneNone
Net Income from Continuous Ops.712.68 Cr.653.87 Cr.467.70 Cr.386.97 Cr.
Net Income Applicable to Common Shares712.68 Cr.653.87 Cr.467.70 Cr.386.97 Cr.

Balance Sheet

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Intangible Assets9.02 Cr.10.79 Cr.11.71 Cr.6.65 Cr.
Capital Surplus001.06 Cr.0
Total Liabilities791.23 Cr.783.09 Cr.719.82 Cr.450.97 Cr.
Stock Holder Equity3264.35 Cr.2995.63 Cr.2598.87 Cr.2245.21 Cr.
Minority Interest0000
Other Liabilities302.94 Cr.221.58 Cr.152.06 Cr.76.39 Cr.
Total Assets4055.58 Cr.3778.72 Cr.3318.69 Cr.2696.18 Cr.
Common Stock17.17 Cr.17.30 Cr.17.45 Cr.17.45 Cr.
Retained Earnings02972.56 Cr.2568.36 Cr.2220.69 Cr.
Other Liabilities125.28 Cr.114.69 Cr.100.94 Cr.72.67 Cr.
Good Will0000
Treasury Stock3247.18 Cr.5.77 Cr.12 Cr.7.07 Cr.
Other Assets109.58 Cr.106.78 Cr.66.44 Cr.73.41 Cr.
Cash211.79 Cr.177.51 Cr.202.35 Cr.95.16 Cr.
Current Liabilities647.38 Cr.648.63 Cr.606.17 Cr.377.64 Cr.
Long Term Asset Charges55.55 Cr.50.10 Cr.25.40 Cr.31.81 Cr.
Short Long Term Debt0000
Other Stockholder Equity3247.18 Cr.5.77 Cr.12 Cr.7.07 Cr.
Property Plant Equipment1647.42 Cr.1629.61 Cr.1582.90 Cr.1423.31 Cr.
Total Cur. Assets2264.46 Cr.2027.59 Cr.1641.71 Cr.1179.81 Cr.
Long Term Investments25.10 Cr.3.95 Cr.15.93 Cr.13 Cr.
Net Tangible Assets3255.33 Cr.2984.84 Cr.2587.16 Cr.2238.56 Cr.
Short Term Investments121.86 Cr.25 Cr.00
Net Receivables1026.18 Cr.832.68 Cr.830.97 Cr.549.37 Cr.
Long Term Debt0000
Inventory791.07 Cr.766.47 Cr.495.68 Cr.435.71 Cr.
Accounts Payable327.17 Cr.373.86 Cr.362.34 Cr.225.18 Cr.

New Offers


Upstox offer
Upstox

Open a demat account through us and get the account opening charges waived off

open paperless account